Design Therapeutics ( NASDAQ:DSGN – Get Free Report ) ‘s stock had its 'market perform' rating reissued by research analysts at SVB Leerink in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. SVB Leerink's price objective would indicate a potential upside of 82.93% from the company's current price. DSGN has been the subject of several other reports. Wedbush lowered Design Therapeutics from an 'outperform' rating to a 'neutral' rating and dropped their price target for the stock from $19.

https://www.dailypolitical.com/2023/08/15/svb-leerink-reiterates-market-perform-rating-for-design-therapeutics-nasdaqdsgn.html

#dailypolitical